Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam

Source: 
Recro Pharma
snippet: 

Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, today announced it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) Office of Drug Evaluation II regarding their New Drug Application (NDA) seeking approval for intravenous (IV) meloxicam for the management of moderate to severe pain.